WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Synthetic Drug Metformin Effective Against Anti-Diabetics

***Abesh Das[1]; Arka Guin[2]; Sayoni Moni[3]; Debolina Kundu[4]; Dr. Samaresh Mondal[5]***

[1]Kolkata Institute of Pharmaceutical Science
[2]Guru Nanak Institute of Pharmaceutical Science and Technology.
[3]Kolkata Institute of Pharmaceutical Science.
[4]Seacom Skill University.
[5]Kolkata Institute of Pharmaceutical Science.

**ABSTRACT**

The biguanide derivative METFORMIN (metformin hydrochloride) has an antihyperglycemic action that is only noticeable in diabetic animals or humans when insulin is secreted. With the exception of near-lethal concentrations, metformin does not, when given alone in humans or non-diabetic animals, cause hypoglycemia at therapeutic dosages.

The beta cells of the pancreas are unaffected by metformin. Metformin's mode of action is not entirely understood. There have been theories circulating that metformin may increase or intensify the effects of insulin at the peripheral receptor location. An increase in the quantity of insulin receptors on cell surface membranes appears to correspond with this enhanced sensitivity. The absorption of metformin might take up to six hours and is somewhat slow. Three urine excretions of the medication occur at a high renal clearance rate of around 450 mL/min. Metformin has an initial fast half-life, lasting anywhere from 1.7 to 3 hours.

The active component, metformin hydrochloride, is present. Metformin is a member of the class of medications known as oral hypoglycemics. It helps your body use the insulin your pancreas produces more effectively, which lowers high blood glucose levels. Insufficient regulation of blood glucose levels is known as diabetes mellitus.

**Keywords:** Biguamide, Metformin, hypoglycemia, half-life

## Introduction

Extended-Release Metformin Hydrochloride Tablets, USP

The oral antihyperglycemic medication metformin hydrochloride extended-release tablets, USP is used to treat type 2 diabetes. There is no pharmacological or chemical relationship between metformin hydrochloride, USP (N,Ndimethyl-monohydrochloride, Imidodicarbonimidic diamide) and any other family of oral antihyperglycemic medications. It is white or almost white in color. A dual hydrophilic polymer matrix structure makes up USP. The "inner" phase of metformin hydrochloride, USP is created by combining it with a drug release regulating polymer. Discrete particles from this "inner" phase are then added to the "external" phase of another polymer. Following ingestion, the tablet is filled with GI tract fluid, which causes the polymers to hydrate and swell. Diffusion via the gel matrix releases the drug gradually from the dosage form and is largely pH-independent. Since the hydrated polymer system is flexible, regular GI tract peristalsis should be able to break it apart. The tablet's biologically inert ingredients may occasionally escape digestion and pass through the GI tract as a soft,


Figure 1: Structure of metformin

***Hypoglycaemia:***

The following are some of the early warning signs: numbness around the lips and tongue; lightheadedness, dizziness, headache, or lack of focus; perspiration; irritability, tearfulness, or sobbing; hunger; and weakness, trembling, or shaking.

***Hyperglycaemia:***

Generally speaking, hyperglycemia (high blood sugar) happens more slowly than hypoglycemia. Hyperglycemia symptoms can include: feeling lethargic or exhausted; headaches; excessive urination; and blurred vision.

**Table 1: Select Mean (±S.D.) Metformin Pharmacokinetic Parameters Following Single or Multiple Oral Doses of GLUCOPHAGE**

| Subject Groups: GLUCOPHAGE dose[a] (number of subjects) | $C_{max}$[b] (µg/mL) | $T_{max}$[c] (hrs) | Renal Clearance (mL/min) |
|---|---|---|---|
| **Healthy, nondiabetic adults:** | | | |
| 500 mg single dose (24) | 1.03 (±0.33) | 2.75 (±0.81) | 600 (±132) |
| 850 mg single dose (74)[d] | 1.60 (±0.38) | 2.64 (±0.82) | 552 (±139) |
| 850 mg three times daily for 19 doses[e] (9) | 2.01 (±0.42) | 1.79 (±0.94) | 642 (±173) |
| **Adults with type 2 diabetes:** | | | |
| 850 mg single dose (23) | 1.48 (±0.5) | 3.32 (±1.08) | 491 (±138) |
| 850 mg three times daily for 19 doses[e] (9) | 1.90 (±0.62) | 2.01 (±1.22) | 550 (±160) |
| **Elderly[f], healthy nondiabetic adults:** | | | |
| 850 mg single dose (12) | 2.45 (±0.70) | 2.71 (±1.05) | 412 (±98) |
| **Renal-impaired adults:** | | | |
| **850 mg single dose** | | | |
| **Mild** ($CL_{cr}$[g] 61-90 mL/min) (5) | 1.86 (±0.52) | 3.20 (±0.45) | 384 (±122) |
| **Moderate** ($CL_{cr}$ 31-60 mL/min) (4) | 4.12 (±1.83) | 3.75 (±0.50) | 108 (±57) |
| **Severe** ($CL_{cr}$ 10-30 mL/min) (6) | 3.93 (±0.92) | 4.01 (±1.10) | 130 (±90) |

[a] All doses given fasting except the first 18 doses of the multiple dose studies

[b] Peak plasma concentration

[c] Time to peak plasma concentration

[d] Combined results (average means) of five studies: mean age 32 years (range 23-59 years)

[e] Kinetic study done following dose 19, given fasting

[f] Elderly subjects, mean age 71 years (range 65-81 years)

[g] $CL_{cr}$ = creatinine clearance normalized to body surface area of 1.73 $m^2$

Figure : Dosage of Metformin for different ages

## Synthesis of Metformin

A standard experiment involved performing a test reaction on a 5 x 20 cm TLC plate, placing a spot of solution containing 0.42 g of dicyanodiamide 1 and 0.4 g of dimethylamine hydrochloride 2 in 5 ml ethanol on the plate, and then subjecting it to MWI at 540 W for 5 minutes, with intervals of 40 seconds. The TLC plate was then operated in the proper system. Metformin hydrochloride 3 was found in a conspicuous position, and its rf value was in line with the standard sample. The reaction was run on a preparative TLC plate in order to obtain a sizable yield of pure product.

A reference TLC plate containing two spots (one of the reactants and the other of the predicted product) was placed on a preparative TLC plate beside an array of reactant spots for the synthesis of metformin hydrochloride. For five minutes, MWI was applied to both plates sporadically at intervals of forty seconds at 540 watts. After viewing the reference TLC in an iodine chamber, the product-containing silicon gel section was scraped off the preparative TLC plate, and the product was extracted using ethyl alcohol.

The intended product yielded 0.82 g (92% yields) upon solvent evaporation.



Figure 2: Synthesis of Metformin

## Mechanism of Action

Metformin is an antihyperglycemic medication that lowers basal and postprandial plasma glucose levels in people with type 2 diabetes, improving their glucose tolerance. Metformin increases peripheral glucose uptake and utilization while lowering intestinal glucose absorption and hepatic glucose synthesis. This leads to an improvement in insulin sensitivity. Metformin does not result in hyperinsulinemia or hypoglycemia in people with type 2 diabetes or in healthy individuals, in contrast to sulfonylureas. Insulin secretion is unaffected by metformin medication, although the day-long plasma insulin response and insulin levels while fasting may actually drop.




Figure 2: Mechanism action of metformin

Glucophage

**Table 2: GLUCOPHAGE vs Placebo Summary of Mean Changes from Baseline* in Fasting Plasma Glucose, $HbA_{1c}$, and Body Weight, at Final Visit (29-week study)**

| | GLUCOPHAGE (n=141) | Placebo (n=145) | p-Value |
|---|---|---|---|
| **FPG (mg/dL)** | | | |
| Baseline | 241.5 | 237.7 | NS** |
| Change at FINAL VISIT | –53.0 | 6.3 | 0.001 |
| **Hemoglobin $A_{1c}$ (%)** | | | |
| Baseline | 8.4 | 8.2 | NS** |
| Change at FINAL VISIT | –1.4 | 0.4 | 0.001 |
| **Body Weight (lbs)** | | | |
| Baseline | 201.0 | 206.0 | NS** |
| Change at FINAL VISIT | –1.4 | –2.4 | NS** |

* All patients on diet therapy at Baseline ** Not statistically significant

## Pharmacokinetics

***Absorption and Bioavailability***

After taking Metformin Hydrochloride Extended-Release Tablets orally once, with a range of 4 to 8 hours and a median value of 7 hours.The amount of absorption (as determined by AUC) is comparable to that of metformin hydrochloride tablets, despite peak plasma levels being around 20% lower at the same dose.

, respectively. The amount of metformin absorbed from metformin hydrochloride extended-release, as determined by AUC.

tablets at a dose of 2000 mg once daily are comparable to metformin hydrochloride tablets given at a dose of 1000 mg twice daily in terms of total daily dose. Metformin did not build up in plasma after repeated delivery of extended-release tablets containing hydrochloride hydrochloride.

The C and AUC of metformin from extended-release metformin hydrochloride tablets exhibit within-subject variability that is similar to those of metformin hydrochloride tablets. meal had no influence on the C and T of metformin, but it did increase the amount of absorption (as determined by AUC) of the metformin hydrochloride extended-release tablets by around 50% when given with meal. Meals with varying fat content showed an identical impact on the extended-release metformin hydrochloride pharmacokinetics.

***Distribution***

After taking 850 mg of metformin hydrochloride orally once, the average apparent volume of distribution (V/F) of the drug was 654 ± 358 L. Whereas sulfonylureas are over 90% protein bound, metformin has very little binding to plasma proteins. Metformin divides, probably with time, into erythrocytes. When metformin hydrochloride tablets are taken according to standard clinical dosages and dosing schedules, steady-state plasma concentrations of the medication are typically obtained in 24 to 48 hours and are less than 1 mcg/mL

***Metabolism and Elimination***

Metformin is eliminated intact in the urine and does not go through hepatic metabolism (no metabolites have been found in humans) or biliary excretion, according to intravenous single-dose trials conducted on healthy participants. Since renal clearance is around 3.5 times higher than creatinine clearance, tubular secretion is most likely the mechanism by which metformin is eliminated. 90% of the absorbed medication is excreted via the renal pathway during the first 24 hours following oral administration.

| ADME/Parameter | Metformin | Telmisartan | Inference | Ref |
|---|---|---|---|---|
| **Absorption (A)**: | OCT1, OCT2, OCT3, OCTN1, PMAT, SERT | Hepatic uptake: OATP1B3; Cellular uptake: OATP2B1 | No interaction | (Kimura et al., 2005;Wishart et al., 2007;Graham et al., 2011;Nakamichi et al., 2013;zu Schwabedissen et al., 2014) |
| **Distribution (D)**: | ENT4 | — | No interaction | (Wishart et al., 2007;Graham et al., 2011) |
| **Metabolism (M)**: | CYP2C11, 2D1, 3A1/2. | UGTs | No interaction | (Choi and Lee, 2006;Wishart et al., 2007) |
| **Excretion (E)**: | OCT1, OCT2, MATE1, Pgp, BCRP | Pgp, Biliary elimination: ABCC2 ABCG2, OATPB3 | Interaction may not occur due to difference in primary route of excretion | (Kimura et al., 2005;Wishart et al., 2007;Deppe et al., 2010;Hemauer et al., 2010;zu Schwabedissen et al., 2014) |

Figure 3: ADME of Metformin

## Formulation & Dosage

Several versions of the generic medication metformin, including tablets, capsules, oral suspensions, oral solutions, and modified-release tablets, are available. Diagemet, Bolamyn, Glucophage, Metabet, Glucient, GlucophageXR, Fortamet, and Glumetza are among the brands under which metformin is sold. The brand name for metformin in liquid form is Riomet. The brand-name glucophage is used to refer to the immediate-release tablet.

Initial dosage instructions for immediate-release metformin are 500 mg twice day or 850 mg once day; maintenance dosage is 2000 mg daily divided into three doses; and maximum dosage is 2550 mg daily.

The recommended starting dosage for the extended-release medication is 500–1000 mg taken once day, with a maximum dosage of 2000 mg. The same daily dosage of metformin modified release can be started by adult patients using standard-release metformin up to 2g per day; however, it is not appropriate if the dosage for the standard-release tablets exceeds 2g per day.

Children younger than ten years old are not authorized to use metformin. First-line therapy for children aged 10 to 17 years old (expert usage only) involves oral administration of 500 mg of immediate-release medication once daily.

If necessary, the maximal dose of a modified-release medication can be taken orally, up to 2g per day. It is advised that adults take 500 mg once daily at first, with the possibility of increasing to 2 mg once daily if needed, with the exception of those with polycystic ovarian syndrome (PCOS). Metformin is occasionally used to treat PCOS, despite the fact that it is not officially licensed to do so. Metformin can be used orally in two to three divided dosages of 1.5–1.7g per day for PCOS patients utilizing immediate-release medications.

Metformin can induce ovulation in patients with PCOS who are anovulatory and premenopausal. However, because there may be variations in the licensing for various formulations containing the same medication, the maximum dosage for metformin immediate-release medications listed in publications and the British National Formulary (BNF) differs from the product license.

## CONTRAINDICATIONS

diabetes mellitus that is unstable and/or insulin-dependent (Type I).

A history of ketoacidosis with or without coma, as well as acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Insulin treatment is recommended for diabetic ketoacidosis.

regardless of the cause, in individuals having a history of lactic acidosis.in patients whose serum creatinine levels are higher than the top limit of the normal range, in the event of renal impairment, or in cases when renal function is unknown.

Renal disease or renal dysfunction, which can be brought on by conditions like cardiovascular collapse (shock), acute myocardial infarction, and septicemia, is indicated by serum creatinine levels of ≥136 μmol/L (males), ≥124 μmol/L (females), or abnormal creatinine clearance.

Heart failure that needs to be treated with medication.

In cases of acute or chronic excessive alcohol intake.

Patients who have clinical or test signs of hepatic disease should typically avoid using TEVA-METFORMIN. This is because severe hepatic dysfunction has been linked to some incidences of lactic acidosis.

When patients are undergoing radiologic examinations that require intravascular injection of iodinated contrast materials, TEVA-METFORMIN should be temporarily stopped., due to the possibility of an abrupt change in renal function when using five of these medicines (see WARNINGS and PRECAUTIONS). In situations involving circulatory collapse and conditions like cardiorespiratory insufficiency, which are frequently linked to hyperlactatemia and hypoxemia.

under stressful circumstances, such as serious infections, trauma, or surgery, as well as throughout the post-surgical recovery period.

in individuals who are extremely dehydrated.

known allergy or hypersensitivity to any of the excipients or metformin HCl.

whilst expecting.

## LACTIC ACIDOSIS

Metformin-associated lactic acidosis has been linked to postmarketing occurrences of resistant bradyarrhythmias, hypothermia, hypotension, and mortality. The onset of metformin-associated lactic acidosis is frequently gradual, with nonspecific symptoms such as myalgias, lethargy, respiratory difficulties, insomnia, and abdominal pain being the sole accompanying symptoms.

***General Precautions***

• ***Lactic acidosis*** –Metformin-associated lactic acidotic deaths have been reported in post-marketing instances, including fatal occurrences.

These cases had a modest onset and were accompanied by nonspecific symptoms including malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence. Elevated blood lactate concentrations (>5 mmol/L), anion gap acidosis (without ketonuria or ketonemia), and an increased lactate: Metformin lowers the amount of lactate that the liver absorbs, raising blood levels of lactate that may raise the risk of lactic acidosis, particularly in individuals who are already at risk when metformin-associated lactic acidosis is detected, metformin hydrochloride extend-release tablets should be stopped right away, and general supportive measures should be implemented right away in a hospital environment. Patients taking extended-release metformin hydrochloride tablets and diagnosed with lactic acidosis are advised to undergo hemodialysis as soon as possible to reverse the effects of the acidosis and flush out any accumulated metformin (metformin hydrochloride can be dialyzed at a rate of up to 170 mL/min in healthy patients). Hemodialysis has frequently led to healing and symptom reversal. The following lists suggestions to lower the risk of and manage metformin-associated lactic acidosis for each known and potential risk factor for the condition:

• ***Renal impairment***— Patients with severe renal impairment constituted the majority of cases of lactic acidosis linked to metformin after it was put on the market. Since the kidneys eliminate a significant amount of metformin, the risk of metformin buildup and metformin-associated lactic acidosis increases with the severity of renal impairment. Considering the patient's renal function, the following clinical recommendations are made.

## Side Effects of Metformin

Metformin is generally well-accepted and has been shown to be both safe and effective. However, the medication's adverse effects make it intolerable for many individuals. Consequently, a thorough awareness of the safety and adverse effects of metformin is necessary for its ideal use. Oral metformin pills may have mild to severe adverse effects. Asthenia, myalgia, upper respiratory tract infection, nausea, abdominal bloating, flatulence, vomiting, diarrhea/constipation, heartburn, headache, agitation, chills, dizziness, fatigue, abdominal cramps or pain, lack of appetite, and an altered or metallic taste are among the common adverse effects.

Nonetheless, data indicates that metformin administration is typically associated with gastrointestinal (GI) symptoms and digestive tract problems. It was found that individuals using metformin experienced higher GI symptoms than those receiving a placebo (average 28% versus 16%, p=0.01). This may be the result of metformin altering the microbiota in the intestines. Although the liver is one of the primary sites of action for metformin, recent studies have revealed that the gut is also impacted by the drug because of its connection to the gut-brain-liver axis. Metformin causes the intestine's bile acids to rise, which may have an impact on the microbiota and, in turn, alter GLP-1 secretion, cholesterol levels, and stool consistency.




Figure 4: Side effects of Metformin

## Conclusion

In summary, the ultimate goal of treating diabetes is to stabilize blood glucose levels. This can be accomplished with the right medications, either taken alone or in combination, and a healthy lifestyle. The first line of treatment for type 2 diabetes is metformin, which is usually a safe and efficient medication. Metformin can assist the body in preventing high blood glucose-related side effects such as retinopathy, diabetic neuropathy, and kidney damage. It facilitates proper food metabolism and restores the body's capacity to react to insulin. There may be a potential higher risk of CVD mortality, and while it is uncommon, metformin buildup in the body can result in a major adverse effect of LA. The potential negative effects of metformin are discussed in this review; however, not every metformin user will experience all of them. Metformin may negatively impact renal function in T2DM patients, perhaps leading to moderate chronic kidney disease. Patients with trauma, fever, congestive heart failure, surgery, renal or hepatic impairment, or advanced age should use metformin with caution. Metformin treatment should also be discontinued before to any kind of surgery.

**Reference**


1. WHO (2019) World Health Organization.
2. Fowler MJ (2008) Microvascular and macrovascular complications of diabetes.Clin Diabetes 26: 77 82.
3. American Diabetes Association (2002) Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 25: 28-32.
4. DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281-303.
5. International Diabetes Federation (2017) IDF Diabetes Atlas (8thEdn.).
6. Dunn CJ, Peters DH (1995) Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721-749.
7. National Institute for Health and Clinical Excellence (NICE) (2015) Type 2 diabetes in adults: Management (NG28).
8. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveysand epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378: 31-40.
9. International Diabetes Federation (2015) IDF diabetes atlas, 6th edition.
10. Fischer J, Ganellin CR, Ganesan A, Proudfoot J (2010) Standalone drugs. In: Ganellin. Analogue-based drug discovery. Weinheim: Wiley-VCH Verlag GmbH & Co.
11. Holman R (2007) Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ Annu Diabetol Hotel Dieu 13-20.

**12.** Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY, et al. (2018) Effect of metformin on kidney function in patients with type 2 diabetes mellitus andmoderate chronic kidney disease. Oncotarget 9: 5416-5423.

**13.** Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 20: CD002967.

**14.** DeFronzo RA, Goodman AM (1995) Efficacy of metformin in patients with non- insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 333: 541-549.

**15.** Johansen K (1999) Efficacy of metformin in the treatment of NIDDM. Meta-analysis. Diabetes Care 22: 33-37.

**16.** Hashimoto H, Mizushima T, Ogura T, Kagawa T, Tomiyama K, et al. (2016) Study on AAV-mediated gene therapy for diabetes in humanized liver mouse to predict efficacy in humans. Biochem Biophys Res Communications 478: 1254-1260.

**17.** Chakraborty A, Chowdhury S, Bhattacharyya M (2011) Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. Diabetes Res Clin Pract 93: 56-62.

**18.** Zheng J, Woo SL, Hu X, Botchlett R, Chen L, et al. (2015) Metformin and metabolic diseases: A focus on hepatic aspects. Front Med 9: 173-186.

**19.** Bailey CJ, Turner RC (1996) Metformin. New England Journal of Medicine 334: 574-579.

**20.** Bosi E (2009) Metformin--the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes Obes Metab 11: 3-8.

**21.** Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393-403.

**22.** Diabetes Prevention Program Research Group (2005) Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the Diabetes Prevention Program: Effects of lifestyle intervention and metformin. Diabetes 54: 2404-2414.

**23.** National Institute for Health and Clinical Excellence (NICE) (2019) Metformin Hydrochloride.

**24.** Lorenzati B, Zucco C, Miglietta S, Lamberti F, Bruno G (2010) Oral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of ActionOral Hypoglycemic Drugs: Pathophysiological Basis of Their Mechanism of Action. Pharmaceuticals (Basel) 3: 3005-3020

**25.** Bristol NJ: Bristol-Myers Squibb (2009) Glucophage (metformin hydrochloride)and Glucophage XR (extended-release) prescribing information.Pg. no: 1-30.